Previous 10 | Next 10 |
2023-08-11 13:35:21 ET AN2 Therapeutics press release ( NASDAQ: ANTX ): Q2 GAAP EPS of -$0.81. R&D expenses increased for the quarter compared to the same period during 2022 due to increased clinical trial expenses, among others. For further details see: AN2 ...
Sufficient patients in screening expected to complete enrollment in Phase 2 portion of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease Expected initiation of Phase 3 portion of pivotal Phase 2/3 study in September AN2 ...
2023-07-05 15:06:02 ET Summary Spero is eligible to receive up to $525 million in development and sales milestone payments as well as royalties on net product sales under the agreement with GSK. In addition, Spero has two other assets that will soon be evaluated in proof-of-concep...
2023-05-26 09:18:10 ET FTSE Russell will rebalance its indexes at the end of June and, as usual, a great deal of buying and selling will come from mutual funds and ETFs to track those changes. The preliminary list of changes came out last week, using April 28 for a cutoff date for marke...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO, will present at the Jefferies Healthcare Con...
2023-05-16 13:08:04 ET Gainers: GD Culture Group Limited ( GDC ) +84% . The Singing Machine Company ( MICS ) +62% . Applied Digital Corporation ( APLD ) +51% . Exela Technologies ( XELA ) +40% . AN2 Therapeutics ( ANTX ) +26% . ...
2023-05-11 17:47:33 ET AN2 Therapeutics press release ( NASDAQ: ANTX ): Q1 GAAP EPS of -$0.79. Cash, cash equivalents and investments totaled $88.5 million at March 31, 2023, which the company expects will be sufficient to fund its operating expenses through mid-2024. ...
Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and...
2023-05-05 13:55:56 ET Summary AN2 is a developer of rare, infectious disease therapeutics. AN2 leverages its boron chemistry expertise and has a history of a successful sale to Pfizer. The company needs cash. AN2 Therapeutics ( ANTX ) is a small company targetin...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO, will present at the JMP Securities Life Scie...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...